發(fā)布時間：2018-06-06 15:44

  本文選題：伏立諾他 + 皮膚T細胞淋巴瘤　； 參考：《中國新藥雜志》2015年08期

【摘要】：伏立諾他作為一種組蛋白去乙�；敢种苿�,已在2006年被美國FDA批準用于皮膚T細胞淋巴瘤(CTCL)的治療,近年來隨著研究的不斷深入,伏立諾他在其他腫瘤治療領域也有了較好的療效,伏立諾他聯(lián)合吉妥單抗及阿扎胞苷治療老年復發(fā)性或難治性急性髓系細胞白血病(AML)有效率可達40%,聯(lián)合地西他濱治療復發(fā)性或難治性急性淋巴細胞白血病(AL)有效率為46.2%,聯(lián)合硼替佐米治療多發(fā)性骨髓瘤(MM)無疾病進展生存期為7.63個月,另外在晚期乳腺癌和骨髓移植患者免疫功能改善方面都有較好的作用。本文通過對伏立諾他近期國外的臨床應用進行了文獻檢索,并將其應用新進展進行綜述。
[Abstract]:As a histone deacetylase inhibitor, volenoate has been approved by the United States FDA in 2006 for the treatment of cutaneous T-cell lymphoma (CTCLs). He also has good results in other areas of cancer treatment. The effective rate of Volinota combined with gitumab and azacytidine in the treatment of recurrent or refractory acute myeloid leukemia (AML) in the elderly can reach 40%, and the effective rate of combination of dicitabine and desitabine in the treatment of recurrent or refractory acute lymphoblastic leukemia (ALL) is up to 40%. The progressive survival time of patients with multiple myeloma (MMM) treated with bortezomil was 7.63 months. In addition, it can improve immune function in patients with advanced breast cancer and bone marrow transplantation. In this paper, a literature review on the recent clinical application of Volinotaxel was carried out, and the new progress in its application was reviewed.
【作者單位】： 國藥一心制藥有限公司;
【分類號】：R979.1

【共引文獻】

相關期刊論文 前10條

1 冀保衛(wèi);陳謙學;田道鋒;吳立權;劉寶輝;郭振濤;王龍;朱曉楠;張申起;;組蛋白去乙�；敢种苿┱T導腦膠質瘤細胞凋亡及其機制的研究[J];中國神經腫瘤雜志;2011年02期

2 馬健;趙名;于曉Y，

本文編號：1987225